CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CytoSorbents (Nasdaq: CTSO) announced a $6.25 million common stock financing and signed an amendment to its credit facility with Avenue Capital Group.
The direct offering is expected to raise approximately $4.0 million in gross cash proceeds. It includes shares at $4.94, shares for directors and certain executives at $5.18, and pre-funded warrants at $4.939. The company plans to repay $3.0 million of principal in cash and issue Avenue 455,465 shares at $4.94 to settle $2.25 million of principal.
The transactions would cut principal by $5.25 million to $12.25 million. CytoSorbents expects to save approximately $0.7 million in interest over 12 months. The amendment extends maturity to July 1, 2028 and extends interest-only payments through March 31, 2028. It also expands Avenue’s rights to convert debt into shares and adds a conditional $250,000 fee.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Principal reduction of $5.25 million would bring Avenue debt from $17.5 million to $12.25 million after closing 32% of market cap
- Major point. Forward-looking: it has not happened yet and may not happen.Direct offering is expected to raise approximately $4.0 million in gross cash proceeds 25% of market cap
- Moderate pointLoan maturity moves back one year, from July 1, 2027 to July 1, 2028
- Moderate pointInterest-only period extends 15 months through March 31, 2028
- Moderate point. Forward-looking: it has not happened yet and may not happen.Interest savings of approximately $0.7 million are expected over 12 months
- Minor pointExisting shareholders, management and directors subscribed for approximately 75% of the offering
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Offering dilution from 556,681 shares at $4.94 and 96,527 shares for directors and certain executives at $5.18
- Major point. Forward-looking: it has not happened yet and may not happen.Avenue share issuance would dilute holders by 455,465 shares at $4.94, settling $2.25 million of principal without raising cash 14% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.First conversion right replaces Avenue’s $2.0 million right with up to $3.0 million of principal convertible at $6.916 per share at any time
- Moderate point. Forward-looking: it has not happened yet and may not happen.Additional conversion right covers up to $3.125 million at $8.645 per share from the earlier of DrugSorb-ATR FDA marketing approval or January 1, 2028
- Minor point. Forward-looking: it has not happened yet and may not happen.Pre-funded warrant dilution covers up to 151,822 shares, with warrants priced at $4.939 and immediately exercisable at $0.001 per share
5 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Final payment of $270,000 accompanies the planned cash repayment
- Minor point. Forward-looking: it has not happened yet and may not happen.Back-end fee of $250,000 is due July 1, 2028 or upon earlier repayment, unless Avenue earns at least 300% net profit on the initial $2.25 million repayment shares
- Minor point. Forward-looking: it has not happened yet and may not happen.Prepayment fee of $52,500 accompanies the planned cash repayment
- Minor point. Forward-looking: it has not happened yet and may not happen.Offering costs include placement agent fees, financial advisor fees and offering expenses payable by CytoSorbents
- Minor point. Forward-looking: it has not happened yet and may not happen.Further three-month interest-only extension requires FDA marketing approval of DrugSorb-ATR by March 31, 2028 and satisfaction of other conditions
Key Figures
- Expected gross cash proceeds
- approximately $4.0 million
- Registered direct offering, before fees and expenses
- Debt reduction
- $5.25 million
- Cash repayment and principal satisfied through share issuance
- Remaining principal
- $12.25 million
- Following the transactions, down from $17.5 million
- Interest savings
- approximately $0.7 million
- Over 12 months
- Debt maturity
- July 1, 2028
- Extended from July 1, 2027
- Interest-only period
- through March 31, 2028
- Further three-month extension available subject to conditions
- First conversion right
- up to $3.0 million at $6.916 per share
- Avenue principal conversion right, exercisable at any time
- Additional conversion right
- up to $3.125 million at $8.645 per share
- Exercisable beginning on the earlier of FDA marketing approval and January 1, 2028
Historical Context
-
Reported approximately $5.7 million cash and quarterly cash burn of approximately $200,000.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
registered direct offering financial
pre-funded warrants financial
shelf registration statement regulatory
beneficial ownership limitations financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
registered direct offering of common stock, led by existing shareholders and management$4.0 million of Avenue debt satisfied through the issuance of common stock at the same offering price$2.25 million - Total debt reduced by
, to$5.25 million , saving approximately$12.25 million in interest over 12 months$0.7 million - Maturity extended one year to July 1, 2028; interest-only period extended 15 months through March 31, 2028
Registered Direct Offering
The Company has entered into securities purchase agreements with certain institutional and accredited investors and certain insiders of the Company for the issuance and sale in a registered direct offering (the "Offering") priced at-the-market under Nasdaq rules of (i) an aggregate of 556,681 shares (the "Common Shares") of the Company's common stock, par value
The Offering is expected to consist of approximately
H.C. Wainwright & Co. is acting as exclusive placement agent for the Offering. WBB Securities, LLC is acting as financial advisor in connection with the Offering.
The Offering is expected to close on or about November 20, 2026, subject to satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately
Avenue Credit Facility Amendment
Concurrently with the Offering, the Company entered into the Third Amendment to Loan Documents (the "Avenue Amendment"), dated November 19, 2026, to its existing Loan and Security Agreement dated June 28, 2024, as amended, with Avenue.
Key terms include:
- Debt reduction of
million: Repayment of$5.25 of principal in cash from the Offering proceeds, plus a$3.0 million prepayment fee and a$52,500 final payment, and satisfaction of$270,000 of principal through the issuance of 455,465 shares of Common Stock to Avenue Venture Opportunities Fund, L.P. at the Offering price of$2.25 million per share. Following these transactions,$4.94 of principal will remain outstanding, down from$12.25 million . The Company expects to save approximately$17.5 million in interest expense over 12 months.$0.7 million - Maturity extended one year: The maturity date is extended from July 1, 2027 to July 1, 2028.
- Interest-only period extended 15 months: Interest-only payments are extended through March 31, 2028, with a further three-month extension available if the Company has received FDA marketing approval for DrugSorb-ATR by that date, subject to other conditions.
- New conversion rights: Avenue's existing
conversion right is replaced with the right to convert (i) up to$2.0 million of principal into Common Stock at$3.0 million per share, equal to$6.916 140% of the Offering price, exercisable at any time, and (ii) up to an additional$4.94 of principal at$3.125 million per share, equal to$8.645 175% of the Offering price, exercisable beginning on the earlier of FDA marketing approval of DrugSorb-ATR and January 1, 2028. Any conversion would further reduce the Company's outstanding debt. - Other terms: The Avenue Amendment also modifies certain beneficial ownership limitations and financial covenants, provides certain registration rights and provides for a back-end fee of
, payable on July 1, 2028 (or earlier repayment) and waived if Avenue achieves a net profit of at least$250,000 300% on the initial repayment shares.$2.25 million
Of the shares issued to Avenue in satisfaction of
Registration and Offering Information
The Common Shares, Pre-Funded Warrants, Pre-Funded Warrant Shares and Registered Shares are being offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-281062), which was declared effective by the
The shares issued to Avenue in satisfaction of the remaining
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, and there shall not be any offer, solicitation or sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.
CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States.
In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.
The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/ or follow us on Facebook and X.
Forward Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, statements regarding the completion and timing of the Offering, the satisfaction of customary closing conditions related to the Offering, and the intended use of net proceeds from the Offering, the expected repayment and conversion of indebtedness under the Avenue Amendment, the expected reduction in interest expense, any future exercise of Avenue's conversion rights, and the timing and outcome of FDA review of DrugSorb-ATR, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. There can be no assurance that the Company will be successful in maintaining its listing of its common stock on the Nasdaq Capital Market. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
ir@cytosorbents.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-announces-6-25-million-common-stock-financing-priced-at-the-market-under-nasdaq-rules-and-concurrent-restructuring-of-avenue-capital-credit-facility-302946616.html
SOURCE Cytosorbents Corp
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.